FREMONT, Calif., May 24 Microfluidic Systems (MFSI), a privately-held company, announced today it has been awarded a series of new patents covering both the components and integrated systems that perform fully automated sample collection through identification of air-borne pathogens such as bacteria, viruses, and toxins. Patent number 7,705,739 entitled "Integrated Airborne Substance Collection and Detection System" covers a combined instrument in which a detect-to-warn component is integrated with a detect-to-treat system. The system which includes a sample collection, biological triggering system, sample processing, amplification, and organism identification, as well as toxin protein detection provide for both an early warning system with a highly specific confirmatory system. Within the automated integrated system are key components and methodologies that MFSI has also patented. For example, another recently issued patent (no. 7,699,915) entitled "Liquid Impingement Unit" optimizes the process of injecting an airborne sample into a liquid-based pathogen processing and detection system.
"We are pleased that our patent and intellectual property portfolio continues to grow in area of automated biological agent detection and identification," commented M. Allen Northrup Ph.D., Founder and CEO. "With these additional patents and our on-going program to build and test these automated systems, we are well on the way to implementing a key solution to airborne pathogen monitoring," he added.
Microfluidic Systems (MFSI), www.microfluidicsystems.com , was founded in 2001 and is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. MFSI personnel have been involved with the development of automated pathogen detection systems and microfluidics for the US Government and commercial markets for over 25 years. For more information, please contact Dr. Northrup at MFSI at 510-354-0400 ext 201, or visit the website, www.microfluidicsystems.com.
Statements in this press release are forward-looking. Actual results might differ from these statements due to unforeseen events and uncertainties. MFSI disclaims any intention to or obligation to update these forward-looking statements.
M. Allen Northrup Ph.D. CEO and Chief Technology Officer MicroFluidic Systems 47790 Westinghouse Dr Fremont, CA 94539 510-354-0400 ext 201 510-354-0404 (fax) firstname.lastname@example.org www.microfluidicsystems.com
SOURCE Microfluidic Systems